Ozempic and Eating Disorders: What's Known and What Isn't

These medications reduce hunger and the motivation to eat, increase fullness by acting on appetite and reward centers in the brain, and slow stomach emptying [1, 2, 4]. In 60–70% of people who take them, significant and sometimes rapid weight loss follows ^[1]. The National Eating Disorders Association (NEDA) flags that rapid weight loss as a particular concern for anyone with an active eating disorder, a history of one, or a high susceptibility to developing one ^[1].

The honest bottom line from the eating disorder field is that nobody knows yet whether these drugs will be helpful, harmful, or neutral for someone with an eating disorder [1, 2]. ANAD, which assembled its guidance after fielding GLP-1 questions from volunteers, group members, mentees, and on its helpline, puts it plainly: critical questions remain unanswered ^[2]. If you have a history of disordered eating, both NEDA and ANAD say the first step is telling your eating disorder specialist and your medical provider before making any decision [1, 2]. For general reader support, NEDA also offers a confidential online screening tool for anyone worried about their eating habits or body image, plus a finder for eating disorder providers and treatment near you or online ^[1].

What are GLP-1 drugs, and which ones does this apply to?

GLP-1 receptor agonists were first approved by the FDA to treat type 2 diabetes and later approved for chronic weight management [1, 2]. The brand names include Mounjaro, Ozempic, Saxenda, Victoza, Wegovy, and Zepbound, and the molecules behind them include semaglutide, liraglutide, and tirzepatide ^[1]. Lower doses of these drugs are used for type 2 diabetes, while higher-dose versions of the same medications are used for weight loss ^[1]. The class was developed in the early 2000s, and newer versions are more potent and produce greater weight loss than earlier ones ^[1].

Dual GLP-1/GIP agonists mimic naturally occurring incretin hormones: they enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety ^[4].

One point matters for this whole discussion: no GLP-1 medication has FDA approval for treating any eating disorder. Any use for that purpose is off-label ^[2].

Is there any research on GLP-1s in people with eating disorders?

Very little. Kim Dennis, MD, writing for NEDA, describes “very little research” on GLP-1s in people with eating disorders and says the short answer is that we don’t know yet ^[1]. NEDA’s review of the scientific literature as of 2024 found “precious little”: a few studies with mixed results ^[1].

Some small studies found decreased binge episodes in people with binge eating disorder or bulimia nervosa — but the samples were very small and follow-up lasted only 3–6 months, leaving longer-term outcomes and risks entirely unknown ^[1]. The one randomized controlled study in binge eating disorder found no change in eating disorder behaviors at all ^[1].

A 2025 narrative review by Krug and colleagues, published November 28, 2025 in the journal Nutrients, reached similar conclusions: GLP-1 receptor agonists reduce hunger and binge-eating frequency, suggesting possible benefit for binge-type eating disorders, but evidence for restrictive eating disorders remains limited ^[3]. The same review found that safety and suicidality data are limited by short follow-up periods and by the fact that trials frequently exclude people with psychiatric conditions ^[3].

What risks do clinicians actually worry about?

NEDA lists specific potential risks for people with eating disorders who take GLP-1s ^[1]:

• Misuse of the drug by people with restrictive eating disorders like anorexia nervosa or atypical anorexia, or purging disorders like bulimia nervosa
• Rapid weight loss and malnourishment, which is a risk factor for refeeding syndrome
• Inability to eat meals and snacks at regular intervals, a standard nutritional approach in eating disorder recovery
• Worsening of cognitive and behavioral eating disorder symptoms — body image concerns, weight obsession, drive for thinness, skipping meals, or over-exercising
• Weight cycling from starting and stopping the medication due to access issues
• Intensified thin idealization, weight stigma, and fatphobia, with disproportionate harm to people in larger bodies
• Ostracism of larger-bodied GLP-1 users by eating disorder and fat-activism communities

NEDA also notes there are no studies examining GLP-1s in people with a past eating disorder, a current one, or future risk ^[1].

ANAD adds that appetite suppression and rapid weight change can destabilize a fragile recovery, because recovery depends on tuning into hunger cues and establishing regular eating patterns ^[2]. The side effects themselves — not just the weight loss — may trigger a relapse, an onset, or worsening of eating disorder symptoms ^[2].

The 2025 Nutrients review raises two more concerns: appetite suppression may reinforce rigid control or perfectionistic traits, and rapid medication-driven weight loss may disrupt body perception ^[3]. Dr. Laura Bridge, speaking on The Curbsiders podcast, cautioned that GLP-1s can worsen restriction by reinforcing malnutrition and blunting hunger cues ^[4].

What physical side effects overlap with eating disorder symptoms?

The most common side effects are nausea, vomiting, and diarrhea, along with constipation, GI discomfort, and reduced appetite [1, 2]. Dr. Bridge’s caution on The Curbsiders is that these medications’ effects — appetite suppression and delayed gastric emptying among them — can unintentionally mimic or exacerbate disordered eating behaviors ^[4].

Other documented risks include gastroparesis, hypoglycemia, bowel obstruction or ileus, pancreatitis, renal failure, hair loss, dehydration, reduction of lean body mass, and risk of thyroid cancer and other thyroid diseases ^[1]. ANAD reports a growing number of patients describing muscle wasting — loss of muscle mass and strength — associated with GLP-1 use ^[2].

On mental health: anecdotal reports of increased suicidal ideation did not appear significant in the FDA’s review of large-scale data ^[1].

Two more facts shape the risk picture. Weight loss on these drugs relies on continued use, and most of the weight is usually regained if the medication is discontinued ^[2]. And insurers often cover only specific uses, the medication can be expensive, and monitoring requires a substantial investment of time ^[2].

Why do eating disorders get missed when these drugs are prescribed?

NEDA points out that eating disorder training and screening are limited in primary care, family practice, pediatrics, and endocrinology ^[1]. People with atypical anorexia or non-purging bulimia are more likely to go undiagnosed or to be misdiagnosed as having binge eating disorder, and people of color are less likely to be diagnosed or to receive specialty eating disorder care ^[1].

The Curbsiders episode makes the same point from the primary care side: eating disorders occur at any BMI, so screening should not be limited to underweight patients, and many eating disorders are missed in outpatient medicine, including among patients presenting for metabolic or weight-related concerns ^[4].

Should a doctor screen for an eating disorder before prescribing a GLP-1?

The Curbsiders guidance is to screen all patients using brief, non-judgmental tools, not just those who appear underweight ^[4]. Three screening instruments came up in that discussion ^[4]:

Screening tool	Items	What it measures	Setting
SCOFF Questionnaire	5 yes/no items	Restrictive and purging behaviors, body-image concern	Primary care
SDE (Screening for Disordered Eating)	5 items, 5-point Likert scale	Cognitive and behavioral features of disordered eating	Primary care
EDE-Q (Eating Disorder Examination Questionnaire)	28 items plus 6 behavioral questions	Shape and weight concerns, restraint, eating concern, binge/purge frequency	Specialty clinics

On diagnosis-specific prescribing, the Curbsiders episode cites Kalas et al (2025): GLP-1s are contraindicated in anorexia nervosa and restrictive eating patterns ^[4]. For bulimia, a GLP-1 receptor agonist can be used with caution for an indicated condition, with careful supervision for relapse ^[4]. For binge eating disorder, GLP-1s show promise in reducing binge frequency by increasing satiety, but they may blunt hunger cues or trigger relapse after discontinuation ^[4].

For context on approved eating disorder medications: fluoxetine is the only FDA-approved medication for bulimia (with monitoring for QT prolongation), and lisdexamfetamine is FDA-approved for binge eating disorder — though it is itself an appetite suppressant ^[4]. There are no approved medications for restrictive eating disorders; SSRIs are used only for co-occurring anxiety or depression ^[4]. Nutrition therapy and psychotherapy are first-line treatment, with a dietitian goal of three meals plus a snack daily ^[4].

Good monitoring has specific parameters. The Curbsiders guidance includes tracking vitals, electrolytes, heart rate changes such as bradycardia, and menstrual changes, with a bone density test if a patient has had amenorrhea or maintained a low weight ^[4]. Dr. Bridge also suggests asking patients “What does health mean to you?” — a question that helps separate health goals from weight-loss goals ^[4].

ANAD recommends working with a physician, therapist, and dietitian who are versed in both GLP-1s and eating disorders, with your full eating disorder history disclosed — and seeking a second opinion if a provider overlooks that history ^[2]. ANAD also suggests using standardized measures like the EDE-Q to track symptoms while on a GLP-1, setting boundaries on the amount and rate of weight loss, and planning an exit strategy before starting ^[2]. NEDA adds that your eating disorder specialist and medical provider should communicate with each other, with regular follow-up for medical monitoring ^[1].

Where are people actually getting these drugs?

A KFF Health Tracking Poll, fielded October 27–November 2, 2025 and published November 14, 2025, found that 18% of US adults have ever taken a GLP-1 and 12% are currently taking one — a 6 percentage point increase from 18 months earlier ^[5].

Among people who have taken one, here’s where the medication came from ^[5]:

Source of medication	Share of users
Primary care provider or specialist	76%
Online provider or website	17%
Medical spa or aesthetic medical center	9%

The poll reports the source of the medication only — it does not measure screening quality at any of these sources ^[5].

Affording these drugs is a strain for many users: 56% of users say the drugs were difficult to afford, one in four say “very difficult,” and 27% have insurance but pay the full cost themselves ^[5]. Current use includes 45% of adults who say they have been diagnosed with diabetes, 29% of those diagnosed with heart disease, and 23% of those diagnosed as overweight or obese in the past five years. By age, 22% of adults 50–64 currently use a GLP-1, compared with 9% of adults 65 and older ^[5].

Who is most interested in GLP-1s, and what does body image have to do with it?

A study published in Body Image (volume 53, June 2025, article 101890) by Markey, August, Malik, and Richeson looked at who wants these drugs ^[6]. The sample was 225 participants from a Northeastern US university, mean age 20.03, 71.2% women ^[6].

The participants most interested in trying GLP-1s and most willing to tolerate side effects reported greater body shame, body surveillance, weight concerns, anti-fat bias, disordered eating behaviors, and higher BMIs — along with lower body appreciation and lower body neutrality ^[6]. BMI and recent weight-loss attempts uniquely accounted for variance in interest and side-effect tolerance ^[6]. Body appreciation moderated one of these findings, suggesting it may act as a protective factor against interest in GLP-1s for weight loss ^[6].

The study is cross-sectional and used a non-clinical university sample, so it cannot establish any causal direction — it shows who is interested, not what happens to them ^[6].

Do people get judged for losing weight with a GLP-1?

Yes, according to two experimental studies — and the judgment attaches to the medication, not just the body.

A study by Post, Stock, and Persky published April 9, 2026 in the APA journal Stigma and Health (with a Georgetown release on April 10, 2026) recruited 402 US women ages 30 to 49 who identified as Black or white and reported being overweight or having obesity ^[7]. Participants read a vignette about a woman named Evette who lost 15% of her body weight either through diet and exercise or with a GLP-1 medication ^[7].

Stigma was higher in the GLP-1 condition across all four measured dimensions: fat phobia, dislike, blame, and desire for social distance ^[7]. The belief that medication-assisted weight loss is a “shortcut” or easy way out was the key mediator predicting all four stigma outcomes ^[7]. Unexpectedly, stigma was higher when Evette was portrayed as white rather than Black, and participants’ own race did not significantly change outcomes in the GLP-1 condition ^[7].

An earlier study by Post and Persky in the International Journal of Obesity (2024;48(7):1019–1026) used 357 US adults with a mean age of 37.8 in a 2×2 design: a woman who was either lean or had obesity, losing 15% of her body weight via diet and exercise or a GLP-1 receptor agonist ^[8]. Negative evaluations were stronger for GLP-1 weight loss than for diet and exercise, driven by shortcut beliefs, irrespective of body size — lean users were judged too ^[8]. The egocentric-impression effect through shortcut beliefs was stronger for the lean woman ^[8].

The backdrop matters: research cited in that study found 57% of US adults have experienced weight stigma, and weight stigma is associated with increased risk of diabetes, eating disturbances, depression, and other physical and mental health harms ^[8]. Post and her colleagues say stigma related to GLP-1 medications may discourage people from seeking evidence-based care or intensify shame for those already managing a chronic condition ^[7].

What about the broader culture around thinness?

The 2025 Nutrients review notes that social media discourse glamorizes thinness and intensifies stigma around GLP-1 use, and that these psychosocial effects intersect with access inequities, disproportionately affecting adolescents and people from culturally diverse or socioeconomically marginalized groups ^[3].

NEDA raises an unanswered question about whether the newer GLP-1s will worsen weight stigma, healthcare disparities for people in larger bodies, and race-based health inequities ^[1]. NEDA also warns against focusing on the drugs’ benefits while ignoring thin idealization, the role of marketing and Big Tech in perpetuating weight stigma, inequities in food access, changes in the food supply, and persisting treatment inequities for communities of color ^[1].

Can GLP-1s ever be part of a care plan?

The documented benefits are real: improved glucose control, lower HbA1c, decreased risk of heart attack or stroke, and decreased cardiovascular mortality ^[1]. ANAD lists potential benefits including better diabetes management, reduced cardiovascular and stroke risk, decreased binge episodes (with limited evidence), and emerging research in addictions ^[2].

For binge-type eating disorders specifically, the mechanisms may be relevant: reduced cravings for highly palatable foods, increased fullness, slowed digestion, possible effects on dopamine pathways, and blood sugar stabilization ^[2]. The 2025 review found GLP-1s reduce binge-eating frequency and reported short-term reductions in emotional eating ^[3].

But ANAD’s position is that medication is never a stand-alone solution — behavioral change, emotional regulation, and regular eating patterns remain central ^[2].

What warning signs should someone watch for while taking a GLP-1?

ANAD’s safety plan elements include frequent monitoring, a plan for side effects, alertness to new or worsening eating disorder behaviors, and discussion of new triggers ^[2]. The dose may need to be lowered or the medication switched if nourishment needs or recovery goals aren’t being met ^[2]. Ongoing discussion with a therapist should be part of monitoring ^[2].

The symptom domains NEDA lists to watch for are body image concerns, weight obsession, drive for thinness, skipping meals, and over-exercising ^[1]. ANAD adds that eating disorders thrive in isolation, so being open with trusted people supports recovery ^[2].

One practical point from the Curbsiders episode: patients on these drugs may not perceive or recognize hunger and fullness cues, which is why mindful eating is taught in that setting ^[4].

What’s settled and what isn’t?

NEDA’s summary: GLP-1s are helpful for type 2 diabetes and reducing cardiovascular mortality, but they can be harmful for people with eating disorders or disordered eating when used for an unintended purpose, inadequately monitored, monitored by clinicians without eating disorder expertise, or used for weight loss motivated by weight stigma or fatphobia — and the same risks apply to people with undiagnosed eating disorders ^[1].

The 2025 review’s conclusion is that GLP-1s sit at the intersection of medical innovation and psychological risk, and that co-designed research and multidisciplinary monitoring are needed ^[3].

What is settled: these drugs reduce hunger, produce significant weight loss in most users, and carry GI and other physical side effects [1, 2]. What is not: their long-term psychological effects in anyone, and their effects — good or bad — in people with current, past, or at-risk eating disorders [1, 2, 3]. Anyone with an eating disorder history considering a GLP-1 should inform both their eating disorder specialist and their medical providers before deciding [1, 2].

Sources

1. National Eating Disorders Association. GLP-1 Receptor Agonists and Eating Disorders.
2. National Association of Anorexia Nervosa and Associated Disorders. GLP-1 Medications & Eating Disorders. April 3, 2025.
3. PubMed Central. Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes.
4. The Curbsiders. #504: Adult Eating Disorders in the GLP-1 Era. November 10, 2025.
5. KFF. KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. November 14, 2025.
6. Body Image (Elsevier). Body image and interest in GLP-1 weight loss medications. June 2025.
7. Georgetown Lombardi Comprehensive Cancer Center. New Study Examines Stigma Toward Women Who Lose Weight Using GLP-1 Medications.
8. PubMed Central. The Effect of GLP-1 Receptor Agonist Use on Negative Evaluations of Women with Higher and Lower Body Weight.
9. International Journal of Obesity. GLP-1 receptor agonists and the emergence of treatment-related stigma: a call for conceptual clarity.
10. Medscape Medical News. Weight Stigma Is Growing Across Social Networks, Do GLP-1 Prescribers Need a New Approach? July 14, 2026.
11. NBC News. Is the era of body positivity over? Some experts worry about return of ‘thinness’ as the norm. December 29, 2024.
12. Vogue. The Vogue Business Fall/Winter 2026 Size Inclusivity Report.
13. ELLE Canada. Skinny Culture Is Back With a Vengeance. So Whatever Happened to Body Positivity? July 20, 2026.
14. TODAY. Lizzo Addresses Weight Loss Backlash, New Body-Positive Movement.
15. USA TODAY. Diet pills, the ’90s and why the GLP-1 craze is worrying some experts. April 30, 2026.
16. University of Colorado Anschutz Medical Campus. Why ‘Skinny’ Culture Is Back – and What It Means for Body Image and Mental Health.
17. Northeastern University. Diet Culture is Back. Is Ozempic Reviving Eating Disorders? August 19, 2026.
18. The Guardian. People’s bodies are changing in the age of Ozempic. How are we meant to talk about it? August 25, 2026.
19. TODAY. Celebrities Who’ve Said They’re On Ozempic, Weight-Loss Drugs.
20. Teen Vogue. How to Talk About Ariana Grande in the Ozempic Era.
21. PubMed Central. Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity.